July 20, 2018 The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first drug in its class (IDH1 inhibitors) and is approved for use with an FDA-approved companion diagnostic used […]Continue Reading ...
July 20, 2018 AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for venetoclax in combination with a hypomethylating agent (HMA) or in combination with low-dose cytarabine (LDAC) for the treatment of newly diagnosed patients with acute myeloid leukemia (AML) […]Continue Reading ...
Bone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: VashiDonsk/Wikipedia/CC BY-SA 3.0 Scientists have discovered that it is possible to identify people at high risk of developing acute myeloid leukaemia (AML) years before diagnosis. The researchers from Wellcome Sanger Institute, European Bioinformatics Institute (EMBL-EBI) and their international collaborators found that patients […]Continue Reading ...
July 10, 2018 An international team of leukemia scientists has discovered how to predict healthy individuals at risk of developing acute myeloid leukemia (AML), an aggressive and often deadly blood cancer. The findings, published today in Nature, illuminate the ‘black box of leukemia’ and answer the question of where, when and how the disease begins, […]Continue Reading ...
April 24, 2018 Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow that comprises 1% of all new cancer cases and almost 2% of cancer deaths in the U.S. The five-year survival rate for the disease is less than 20%. Researchers at the Cancer Science Institute of Singapore (CSI Singapore) at […]Continue Reading ...
ivosidenib Treatment for Acute Myeloid Leukemia FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation CAMBRIDGE, Mass., Feb. 15, 2018 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced […]Continue Reading ...
September 1, 2017 Pfizer Inc. nowadays introduced that the U.S. Meals and Drug Management licensed MYLOTARG™ (gemtuzumab ozogamicin) for adults with newly identified CD33-positive acute myeloid leukemia (AML), and adults and kids 2 years and older with relapsed or refractory CD33-positive AML. MYLOTARG is the primary remedy with a sign that incorporates pediatric AML. It […]Continue Reading ...
September 1, 2017 — The U.S. Meals and Drug Management as of late licensed Mylotarg (gemtuzumab ozogamicin) for the remedy of adults with newly identified acute myeloid leukemia whose tumors specific the CD33 antigen (CD33-positive AML). The FDA additionally licensed Mylotarg for the remedy of sufferers elderly 2 years and older with CD33-positive AML who’ve […]Continue Reading ...
July 17, 2018 For the first time, a team of international researchers have mapped the family trees of cancer cells in acute myeloid leukemia (AML) to understand how this blood cancer responds to a new drug, enasidenib. The work also explains what happens when a patient stops responding to the treatment, providing important clues about […]Continue Reading ...
By Sally Robertson, BScJuly 11, 2018 Researchers from Cincinnati Children’s Hospital have made important discoveries about the molecular mechanisms driving acute myeloid leukemia (AML), a deadly pediatric cancer. The findings could lead to the development of new treatments. MLL-AF9 Leukemia Cells. (Image Credit: Cincinnati Children’s) Writing in the Journal of Experimental Medicine, the scientists refer […]Continue Reading ...
May 18, 2018 Researchers from the Albert Einstein College of Medicine in New York have discovered that a signaling protein elevated in patients with acute myeloid leukemia (AML) plays a much wider role in the disease than previously thought. The study, which will be published May 17 in the Journal of Experimental Medicine, raises hopes […]Continue Reading ...
April 11, 2018 In a study published online today in Science Translational Medicine, Albert Einstein College of Medicine researchers report that an experimental peptide (small protein) drug shows promise against the often-lethal cancer acute myeloid leukemia (AML) and describe how the drug works at the molecular level. The findings have led to a Phase I/II […]Continue Reading ...
FRIDAY, Sept. 1, 2017 (HealthDay Information) — The U.S. Meals and Drug Management on Friday licensed an altered dose of the drug Mylotarg to regard a particular form of acute myeloid leukemia — CD33-positive AML. An previous model of the drug were withdrawn from the marketplace when well being dangers began to emerge. Identified generically […]Continue Reading ...
September 1, 2017 The U.S. Meals and Drug Management lately authorized Mylotarg (gemtuzumab ozogamicin) for the remedy of adults with newly recognized acute myeloid leukemia whose tumors categorical the CD33 antigen (CD33-positive AML). The FDA additionally authorized Mylotarg for the remedy of sufferers elderly 2 years and older with CD33-positive AML who’ve skilled a relapse […]Continue Reading ...
FRIDAY, Sept. 1, 2017 — The U.S. Meals and Drug Management on Friday licensed an altered dose of the drug Mylotarg to regard a particular form of acute myeloid leukemia — CD33-positive AML. An previous model of the drug have been withdrawn from the marketplace when well being dangers began to emerge. Identified generically as […]Continue Reading ...
- In the addiction battle, is forced rehab the solution?
- Busting myths about milk – Scope
- Platelet-rich plasma does not enhance cartilage formation capabilities of stem cells
- Wearable devices and ‘mhealth’ technology emerge as promising tools for better health
- Phase 2 Clinical Data Published Showing Summit’s Ridinilazole Preserved Gut Microbiome of Patients with CDI
- Cardiac progenitor cells undergo a cell fate switch to build coronary arteries
- Revealed: The molecular mechanism underlying hypertrophic cardiomyopathy, or “workaholic heart”
- Diabetes epidemic in Guatemala driven by aging, not obesity
- New technology shows potential to streamline the analysis of proteins
- Rethinking the stroke rule ‘time is brain’
- Incidence of coronary artery compression in children may be more common than previously thought
- Study helps to better understand disease caused by Alpha-1 antitrypsin deficiency
- AI platform identifies acute neurological illnesses faster than human diagnosis
- American College of Rheumatology receives grants to support development of lupus clinical trials
- New study explains why women get more migraines than men
- American Heart Association Urges Screen Time Limits for Youth
- Brief interventions during routine care reduce alcohol use among men with HIV
- New genome analysis could identify people at higher risk of common deadly diseases
- NIH grant for Mount Sinai to study use of inhaled corticosteroids for treatment of sickle cell disease
- Daicel supplies free nanodiamond samples to international researchers